The effect of landiolol on rehospitalization for heart failure in patients with acute heart failure and atrial fibrillatio
Not Applicable
- Conditions
- Acute heart failure with tachycardic atrial fibrillation
- Registration Number
- JPRN-UMIN000020290
- Lead Sponsor
- The Cardiovascular Institute
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Not provided
Exclusion Criteria
1)Taking any oral beta-blocker 2)Patients required electronic shock 3)Severe valve stenosis 4)Acute coronary syndrome 5)Hyperthyroidism or its prospects 6)Hypotension less than 100mmHg 7)Pacemaker implanted or ICD implanted 8)Under respirator 9)Cardiogenic shock 10)Assessed as not being suitable for applicants
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie landiolol's effect on rehospitalization in acute heart failure with tachycardic atrial fibrillation?
How does landiolol compare to standard beta-blockers in reducing rehospitalization rates for acute heart failure with atrial fibrillation?
Which biomarkers predict response to landiolol in patients with acute heart failure and tachycardic atrial fibrillation?
What are the potential adverse events of landiolol in acute heart failure patients with atrial fibrillation and how are they managed?
How does landiolol compare to esmolol in managing acute heart failure with tachycardic atrial fibrillation and rehospitalization risk?